Acetylcholine Receptor Antibody EQA
| Accreditation Status: | UKAS Schedule of Accreditation | ||||||||
| Date Scheme started: | 1991 | ||||||||
| Clinical Applicability: | Diagnosis and monitoring of Myasthenia Gravis | ||||||||
| Analytes: | ACR (SER/008) | ||||||||
| Units for Reporting: | Qualitative responses phospholipid antibodies; Quantitative responses in GPLU/mL and MPLU/mL | ||||||||
| Samples Distributed: |
Liquid format. Normal and pathological human serum Additional materials may be produced for specific recovery experiments by the addition of a reference serum to an analyte-free serum matrix |
||||||||
| Number of Distributions per year: | 4 | ||||||||
| Number of Samples per Distribution: | 3 | ||||||||
| Frequency of Distributions: | Every two months as outlined in the Distribution Schedule | ||||||||
| Schedule of Analysis: | Data entry is via the web for the submission of results. Data analysis commences 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics. | ||||||||
| Data Analysis: | Qualitative responses are recorded for each analyte and assessed in relation to the designated response. Reports show method or kit related statistics in terms of Method Laboratory Trimmed Mean (MLTM) and range of results reported | ||||||||
| Performance Scoring: | MI Scoring | ||||||||
| Criteria of Performance: |
Laboratory performance is assessed over a running analytical window of 4 Distributions (12 months) The categories of performance are:
|
||||||||
| Persistent Poor Performance: |
Defined as being in the Poor Performance category for two or more successive Distributions |